Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of LNP023 in primary IgA nephropathy
CTR20210848Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Iptacopan in IgA nephropathy (IgAN), sponsored by Novartis. Started Feb 2022; status: completed.
02
Drugs
Iptacopan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20210848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210848.